Turn Therapeutics (TTRX) Other Non Operating Income (2025 - 2026)
Turn Therapeutics (TTRX) posted quarterly Other Non Operating Income of $5578.0 for Q1 2026, down 89.12% year-over-year from $51285.0 in Q1 2025, and down 95.39% quarter-over-quarter from $120975.0 in Q4 2025.
Powered by 
Analysis
Turn Therapeutics (TTRX) Other Non Operating Income (2025 - 2026) Analysis & Trends
Turn Therapeutics' Other Non Operating Income history runs 2 years deep, the most recent figure standing at $5578.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 89.12% year-over-year to $5578.0; the TTM figure through Mar 2026 stood at $182098.0 (changed N/A YoY), while the FY2025 annual figure was $176520.0, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at $5578.0, down from $120975.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $120975.0 in Q4 2025, with the low at $4260.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Turn Therapeutics | 305.18 Mn | 305.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34 Mn |
| Mar 31, 2026 | 697,561.00 |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 4,260.00 |
| Jun 30, 2025 | 120,975.00 |
| Mar 31, 2025 | 51,285.00 |